Regulatory Winds & Execution Catalyze GoHealth's Upside

Moretus Research initiates coverage of GoHealth (GOCO) with a Strong Buy rating and a $20 price target, implying a 246% upside, based on anticipated revenue growth exceeding consensus estimates, driven by regulatory tailwinds and improved execution. The firm projects FY25E revenue of $890 million and FY26E revenue of $960 million. A key risk identified is potential regulatory scrutiny of Medicare Advantage broker compensation, which could lead to multiple compression.

Analysis

Moretus Research has initiated coverage on GoHealth, Inc. (GOCO) with a 'Strong Buy' rating and a $20 price target, implying a significant 246% upside from current levels. This positive initiation is driven by the view that the market undervalues both regulatory tailwinds and an execution-driven inflection in GoHealth's revenue and profitability. Moretus Research projects GoHealth's FY25E revenue at $890 million, an 11.4% year-over-year increase, and FY26E revenue at $960 million, a 7.9% year-over-year increase, with both forecasts notably exceeding consensus estimates. The price target is based on a 0.23x forward price-to-sales multiple applied to the FY26E revenue projection. While bullish, the analysis identifies a key risk stemming from potential regulatory or legal pressure, particularly concerning recent scrutiny of Medicare Advantage (MA) broker compensation and compliance, which could lead to multiple compression despite strong operational execution. Nevertheless, Moretus Research believes the current market discount on GOCO shares is unwarranted and recommends accumulation, citing GoHealth's position as a leading digital Medicare and health insurance brokerage utilizing AI-based plan optimization and an asymmetric risk-reward profile.

Key Decisions for Investors

• Investors should consider the 'Accumulate' recommendation for GoHealth shares, given the analyst's outlook for significant upside potential based on an execution-driven turnaround and underappreciated regulatory tailwinds.
• Carefully monitor any developments related to regulatory scrutiny of Medicare Advantage broker compensation and compliance, as this is highlighted as a key risk that could compress valuation multiples, even with strong company performance.
• Track GoHealth's forthcoming revenue figures against Moretus Research's above-consensus estimates of $890 million for FY25 and $960 million for FY26 to assess the progression of the firm's execution-driven growth thesis.